Would Merck Be the Best Buyer for AstraZeneca?

Pfizer (PFE) may be preparing to make a bid for AstraZeneca (AZN), but Merck & Co (MRK) would be a better suitor.

Apr 30, 2014 at 6:30PM

Pfizer (NYSE:PFE) has already been rejected by AstraZeneca (NYSE:AZN) twice, but rumors suggest Pfizer may be considering another, higher bid for the company. While adding AstraZeneca's diabetes and oncology pipeline would bulk-up Pfizer nicely, Merck & Co. (NYSE:MRK) might be a better suitor.

While Merck isn't rumored to be looking at AstraZeneca, there are a lot of reasons such a deal might make sense.

Merck is already a leader in diabetes treatment thanks to its top selling Januvia, which means it could quickly integrate AstraZeneca's diabetes drugs into its existing sales team. Merck also has a strong presence in heart disease, and respiratory, and is building out an oncology business that could benefit from profit-friendly cost savings if it were to acquire AstraZeneca.

Given all those synergies, let's take a closer look at why the two might make a picture perfect combination.

MRK Chart

MRK data by YCharts

Adding horses to the stable
Merck is the planet's third biggest seller of diabetes medication, but all of its diabetes sales come from just one drug: Januvia. That one drug, however, is a blockbuster. Januvia's sales totaled more than $1.3 billion in the first quarter. And importantly, Januvia's patent is protected until 2022, which means there's plenty of time to continue ringing up sales.

But just because Januvia is a top seller with a long runway, doesn't mean Merck couldn't make more money if it had more products to sell. That's because it costs a lot to hire, train, and maintain a sales force large enough to serve the diabetes community. As a result, those sales and marketing costs aren't being leveraged to their fullest.  

That would change quickly if Merck were to acquire AstraZeneca. AstraZeneca acquired the half of its diabetes partnership it didn't own from Bristol-Myers Squibb in December, giving AstraZeneca complete control over diabetes drugs that represent more than $1 billion in annual sales.

Among the drugs Merck could begin pitching would be AstraZeneca's two GLP-1 drugs, Byetta and Bydureon. Merck would also get its hands on AstraZeneca's newly approved Farxiga.

Farxiga, which got the FDA green-light in January, is the second SGLT2 diabetes drug approved by the FDA and while AstraZeneca didn't break out Farxiga's first quarter sales, analysts think it could have billion dollar potential.

Since Merck has its own SGLT2 drug in late stage trials, its already acutely aware of the market for Farxiga, and if Merck does go on to win approval for ertugliflozin, which it's co-developing with Pfizer, it could have more options and opportunities than competitors like Johnson & Johnson, the company behind Invokana -- the first approved SGLT2 diabetes drug.

Merck has MK-1293, an insulin, and MK-3102, a DPP-4 inhibitor in late-stage trials, too. Given that Merck has clearly made a choice to bulk up its diabetes franchise, acquiring AstraZeneca's products could dovetail nicely.

Leveraging other indications
In addition to diabetes drugs, AstraZeneca also markets a slate of other drugs that would also benefit Merck.

AstraZeneca's best-selling drug is Crestor, a cholesterol-battling statin that would complement Merck's Zetia and Vytorin cholesterol drugs nicely. Crestor sales totaled more than $1.3 billion in the first quarter. While Crestor will lose patent protection in 2016, Merck would have plenty of time to remove overlapping marketing costs to make the drug more viable in the meantime.

Merck's push into cancer treatment would also benefit from putting AstraZeneca's oncology sales and research team to work.

The EU is considering conditional approval for vintafolide, Merck's ovarian cancer drug. Vintafolide was developed by Endocyte (NASDAQ:ECYT), and Merck signed on as a partner in 2012 in a deal that could eventually cost Merck $1 billion, depending on milestone payments. In March, a key EU advisory panel recommended the drug's conditional approval based on impressive trial results. 

Merck is also developing MK-3475, a promising cancer drug that is in trials as a treatment for melanoma and non-small-cell lung cancer.

If acquired, AstraZeneca would give Merck five additional oncology drugs that are already on the market and have global quarterly sales of more than $750 million.  

Additionally, Merck would get some promising oncology drugs in its pipeline, including olaparib. Olaparib could get the EU nod as a treatment for BRCA mutated ovarian cancer this year and is also being studied in BRCA mutated breast cancer.

Merck could also apply what it's learned in winding down Singulair, which lost patent protection in 2012, to AstraZeneca's Symbicort, which is going off patent this year. AstraZeneca's Symbicort and Pulmicort produced more than $1 billion in revenue last quarter, and despite facing generic competitors, Singulair sales still totaled $270 million in the first quarter for Merck.

Fool-worthy final thoughts
Merck is reportedly near selling its $2 billion-a-year consumer-care business for as much as $10 billion to $14 billion. That could go a long way toward the cash portion of a M&A offer, especially considering Merck is already sitting on more than $15 billion in cash. And while Pfizer is a bit bigger, with a market cap north of $200 billion, Merck isn't that much smaller at $170 billion. That suggests it has plenty of punch to execute such a deal. Whether it will is another question altogether, but it's interesting to think about and could be a great potential deal.

Top dividend stocks for the next decade -- is Merck on the list?
The smartest investors know that dividend stocks simply crush their non-dividend-paying counterparts over the long term. That's beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor's portfolio. To see our free report on these stocks, just click here now.


Todd Campbell has no position in any stocks mentioned. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may or may not have positions in the companies mentioned. Todd owns Gundalow Advisors, LLC. Gundalow's clients do not have positions in the companies mentioned.

The Motley Fool recommends and owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.

Compare Brokers